In a world where healthcare innovation is crucial, GE HealthCare Technologies Inc. is at the forefront, revolutionizing the way we diagnose and treat patients. With its cutting-edge imaging solutions and patient care technologies, the company not only enhances clinical outcomes but also impacts lives globally. Renowned for its quality and commitment to advancing medical science, GEHC has positioned itself as a key player in the healthcare information services industry. As we delve into the investment potential of GE HealthCare, we must consider whether its current fundamentals support its market valuation and future growth prospects.
Table of contents
Company Description
GE HealthCare Technologies Inc. (ticker: GEHC), founded in 2022 and headquartered in Chicago, IL, operates at the forefront of the healthcare information services industry. With a market capitalization of approximately $39B, GEHC specializes in the development, manufacture, and marketing of advanced products, services, and digital solutions for patient diagnosis, treatment, and monitoring. The company’s offerings are organized into four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. Key markets include the U.S., Canada, Europe, and parts of Asia. By leveraging innovation and a robust ecosystem, GE HealthCare plays a pivotal role in enhancing patient outcomes and shaping the future of medical technology.
Fundamental Analysis
In this section, I will analyze GE HealthCare Technologies Inc. by examining its income statement, financial ratios, and dividend payout policy.
Income Statement
Below is the condensed income statement for GE HealthCare Technologies Inc. for the last five fiscal years, providing key financial metrics for analysis.
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 17.16B | 17.59B | 18.34B | 19.55B | 19.67B |
| Cost of Revenue | 10.40B | 10.41B | 11.16B | 11.63B | 11.47B |
| Operating Expenses | 4.05B | 4.38B | 4.66B | 5.49B | 5.58B |
| Gross Profit | 6.77B | 7.17B | 7.18B | 7.92B | 8.21B |
| EBITDA | 3.41B | 3.54B | 3.17B | 3.51B | 3.67B |
| EBIT | 2.78B | 2.92B | 2.53B | 2.90B | 3.09B |
| Interest Expense | 0.07B | 0.04B | 0.09B | 0.54B | 0.51B |
| Net Income | 2.00B | 2.25B | 1.92B | 1.57B | 1.99B |
| EPS | 4.41 | 4.90 | 4.22 | 3.04 | 4.37 |
| Filing Date | — | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
Interpretation of Income Statement
Over the last five years, GE HealthCare has shown a steady increase in Revenue, peaking at 19.67B in 2024, while Net Income has experienced fluctuations, ultimately reaching 1.99B. Notably, the Gross Profit margin has improved from 39.4% in 2020 to 41.7% in 2024, indicating better cost management. In 2024, while Revenue increased modestly, Net Income rose significantly, suggesting improved operational efficiency. The slight rise in EPS reflects positive investor sentiment, despite the pressures of higher operating expenses and interest expenses.
Financial Ratios
The table below presents the financial ratios for GE HealthCare Technologies Inc. over the last few fiscal years.
| Metrics | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net Margin | 12.78% | 10.45% | 8.02% | 10.13% |
| ROE | 23.59% | 20.48% | 21.98% | 23.59% |
| ROIC | 11.25% | 9.56% | 6.79% | 8.29% |
| P/E | 12.14 | 13.83 | 22.44 | 17.89 |
| P/B | 1.64 | 2.83 | 4.93 | 4.22 |
| Current Ratio | 0.97 | 1.09 | 1.00 | 0.99 |
| Quick Ratio | 0.68 | 0.79 | 0.78 | 0.79 |
| D/E | 0.03 | 0.92 | 1.38 | 1.11 |
| Debt-to-Assets | 1.66% | 31.36% | 30.39% | 28.34% |
| Interest Coverage | 69.88 | 29.33 | 4.49 | 5.20 |
| Asset Turnover | 0.67 | 0.67 | 0.60 | 0.59 |
| Fixed Asset Turnover | 7.87 | 7.93 | 7.82 | 7.71 |
| Dividend Yield | 0% | 0% | 0.12% | 0.15% |
Interpretation of Financial Ratios
Analyzing GE HealthCare Technologies Inc. (GEHC) as of FY 2024, the liquidity ratios indicate a current ratio of 0.996 and a quick ratio of 0.793, highlighting potential concerns regarding short-term financial health. The solvency ratio stands at 0.105, signaling a moderate level of debt relative to equity, which may raise red flags for investors. Profitability ratios show a net profit margin of 10.13%, suggesting decent profitability, yet the return on equity (ROE) at 23.59% reflects strong performance for shareholders. Efficiency ratios, including an asset turnover of 0.595, indicate room for improvement in asset utilization. Overall, while profitability appears solid, liquidity and solvency ratios warrant caution.
Evolution of Financial Ratios
Over the past five years, GEHC’s financial ratios have exhibited mixed trends. The current ratio has declined from 1.087 in 2022 to 0.996 in 2024, indicating increased liquidity challenges, while the net profit margin has improved from 8.02% in 2023 to 10.13% in 2024, reflecting enhanced profitability.
Distribution Policy
GE HealthCare Technologies Inc. (GEHC) currently pays a modest dividend of $0.12 per share, reflecting a low payout ratio of approximately 2.76%. This indicates a strong commitment to reinvesting profits for growth while maintaining a sustainable distribution policy. Notably, the company also engages in share buybacks, which can enhance shareholder value. However, investors should consider potential risks associated with low dividend yields and the reliance on share repurchases for value creation, ensuring long-term sustainability remains a priority.
Sector Analysis
GE HealthCare Technologies Inc. operates in the Medical – Healthcare Information Services industry, specializing in diagnostic and monitoring solutions, competing with major firms while leveraging strong product diversification and innovation.
Strategic Positioning
GE HealthCare Technologies Inc. (GEHC) holds a significant share in the healthcare information services market, driven by its diverse product segments including Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. As of now, the company’s market cap stands at approximately $39B. However, it faces competitive pressure from other healthcare technology firms and must navigate potential technological disruptions, particularly in digital health solutions. With a beta of 1.244, GEHC exhibits slightly higher volatility compared to the market, necessitating prudent risk management for investors.
Revenue by Segment
The following chart illustrates the revenue distribution across GE HealthCare Technologies Inc.’s segments for the fiscal years ending in 2023 and 2024.
Analyzing the revenue trends, the Imaging Segment remains the largest contributor, though it has seen a decline from 10.58B in 2023 to 8.86B in 2024. The PCS Segment has remained relatively stable, generating around 3.12B, while the PDx Segment experienced modest growth from 2.31B to 2.51B. The notable absence of the Ultrasound Segment in 2024 indicates a strategic shift which could impact future performance. Overall, GEHC’s revenue growth has slowed, presenting potential margin pressures and concentration risks within its core segments.
Key Products
Below is a table summarizing the key products offered by GE HealthCare Technologies Inc. These products play a crucial role in the medical and healthcare information services industry.
| Product | Description |
|---|---|
| Molecular Imaging | Advanced imaging technology used for detailed visualization of biological processes in the body. |
| Computed Tomography (CT) | High-resolution imaging that provides cross-sectional views of the body for accurate diagnosis. |
| Magnetic Resonance Imaging (MR) | A non-invasive imaging technique that uses magnetic fields to visualize internal structures. |
| Ultrasound Solutions | Devices and systems for radiology, point-of-care, and handheld ultrasound used in various medical fields. |
| Patient Monitoring Devices | Comprehensive solutions for real-time monitoring of patients’ vital signs and health conditions. |
| Diagnostic Cardiology | Equipment and services for the assessment and monitoring of cardiovascular health. |
| Contrast Media Pharmaceuticals | Agents used to enhance the visibility of tissues during imaging exams, improving diagnostic accuracy. |
| Radiopharmaceuticals | Molecular tracers used in imaging scans to identify and diagnose conditions at a cellular level. |
Each of these products reflects GE HealthCare’s commitment to advancing healthcare technology and improving patient outcomes.
Main Competitors
In the competitive landscape of the healthcare information services sector, GE HealthCare Technologies Inc. faces several notable competitors. Below is a summary table illustrating the main companies in this industry, sorted by their market capitalization:
| Company | Market Cap |
|---|---|
| Cardinal Health, Inc. | 47.24B |
| Insmed Incorporated | 43.51B |
| Agilent Technologies, Inc. | 41.25B |
| Alcon Inc. | 39.93B |
| GE HealthCare Technologies Inc. | 39.03B |
| IQVIA Holdings Inc. | 38.46B |
| ResMed Inc. | 37.60B |
| BeOne Medicines Ltd. | 34.50B |
| Humana Inc. | 31.01B |
| Mettler-Toledo International Inc. | 28.90B |
| Koninklijke Philips N.V. | 25.72B |
These companies primarily operate within the North American and global markets, focusing on the provision of medical devices and healthcare solutions. The competition is robust, with firms leveraging technology and innovation to enhance patient care and streamline operations.
Competitive Advantages
GE HealthCare Technologies Inc. (GEHC) holds a strong competitive edge within the healthcare industry due to its diverse portfolio that encompasses advanced imaging technologies, ultrasound solutions, and patient care products. The company’s commitment to innovation ensures a steady pipeline of new products, particularly in molecular imaging and digital health solutions. With ongoing expansion into emerging markets like China and Africa, coupled with strategic partnerships, GEHC is well-positioned to leverage growth opportunities in the healthcare sector, enhancing its market presence and driving future profitability.
SWOT Analysis
The purpose of this analysis is to evaluate the strategic strengths, weaknesses, opportunities, and threats of GE HealthCare Technologies Inc. (GEHC).
Strengths
- Strong market position
- Diverse product portfolio
- Innovative technology
Weaknesses
- High dependency on healthcare spending
- Limited international presence
- Recent IPO challenges
Opportunities
- Expansion into emerging markets
- Growth in telehealth solutions
- Increasing demand for diagnostic imaging
Threats
- Intense competition
- Regulatory changes
- Economic downturn impacts
Overall, this SWOT analysis indicates that while GEHC has a solid foundation and opportunities for growth, it must navigate various challenges and risks in the healthcare industry. Strategic focus on innovation and expanding market reach will be crucial for maximizing its potential.
Stock Analysis
Over the past year, GE HealthCare Technologies Inc. (GEHC) has exhibited significant price movements, reflecting a robust bullish trend with notable trading dynamics.
Trend Analysis
The stock has experienced a percentage change of +12.2% over the past year, indicating a bullish trend. The trend shows acceleration, with a standard deviation of 7.27, suggesting some volatility. The highest price reached was $93.87, while the lowest was $60.51, reflecting a solid upward trajectory.
Volume Analysis
In the last three months, trading volumes total approximately 1.93B shares, with buyer-driven activity dominating at 53.64%. The volume trend is increasing, with the most recent period showing a slightly buyer-dominant behavior at 56.33%. This suggests positive investor sentiment and strong market participation.
Analyst Opinions
Recent analyst recommendations for GE HealthCare Technologies Inc. (GEHC) indicate a strong consensus leaning towards a buy. Analysts have rated the company with an A-, highlighting its solid return on equity (5) and return on assets (5), which demonstrate effective management of resources. The overall score of 4 reflects confidence in GEHC’s growth potential, although there are concerns regarding its debt-to-equity (2) and price metrics (2). Analysts suggest that the company’s innovative healthcare solutions will drive long-term value, making it a favorable investment in 2025.
Stock Grades
The latest stock ratings for GE HealthCare Technologies Inc. (GEHC) reflect a consistent outlook from various reputable grading companies.
| Grading Company | Action | New Grade | Date |
|---|---|---|---|
| BTIG | Maintain | Buy | 2025-11-21 |
| Evercore ISI Group | Maintain | Outperform | 2025-10-30 |
| Morgan Stanley | Maintain | Equal Weight | 2025-10-30 |
| Wells Fargo | Maintain | Overweight | 2025-10-30 |
| BTIG | Maintain | Buy | 2025-10-13 |
| Citigroup | Downgrade | Neutral | 2025-10-07 |
| Morgan Stanley | Maintain | Equal Weight | 2025-07-31 |
| Citigroup | Maintain | Buy | 2025-07-31 |
| Citigroup | Maintain | Buy | 2025-07-09 |
| Morgan Stanley | Maintain | Equal Weight | 2025-05-06 |
Overall, the trend indicates a stable assessment with several companies maintaining their ratings, although Citigroup’s recent downgrade to “Neutral” suggests a cautious sentiment that investors should consider.
Target Prices
The consensus among analysts indicates a positive outlook for GE HealthCare Technologies Inc. (GEHC).
| Target High | Target Low | Consensus |
|---|---|---|
| 90 | 74 | 84.8 |
Overall, the target prices suggest that analysts expect GEHC to perform well, with a consensus price indicating solid potential for growth.
Consumer Opinions
Consumer sentiment about GE HealthCare Technologies Inc. (GEHC) reflects a blend of appreciation for innovation and concerns regarding customer service.
| Positive Reviews | Negative Reviews |
|---|---|
| “Innovative products that truly enhance patient care.” | “Customer service response times are frustratingly slow.” |
| “Reliable technology that consistently delivers results.” | “Pricing is higher compared to competitors.” |
| “Great user-friendly interfaces on their devices.” | “Some products have a steep learning curve.” |
Overall, consumer feedback indicates that while GEHC excels in innovation and reliability, there are notable concerns regarding customer service and pricing that could impact user satisfaction.
Risk Analysis
In evaluating GE HealthCare Technologies Inc. (GEHC), it is essential to understand the potential risks that could impact investment decisions. Below is a summary of the key risks associated with the company.
| Category | Description | Probability | Impact |
|---|---|---|---|
| Market Competition | Intense competition from other health tech firms | High | High |
| Regulatory Changes | Potential changes in healthcare regulations | Medium | High |
| Supply Chain Issues | Disruptions in supply chains affecting production | Medium | Medium |
| Technological Obsolescence | Rapid advancements may outdate current products | High | Medium |
| Economic Downturn | Economic instability affecting healthcare budgets | Medium | High |
The most pressing risks for GEHC are intense market competition and potential regulatory changes. With the healthcare sector’s rapid evolution and increasing scrutiny, these factors could significantly impact the company’s market position and profitability.
Should You Buy GE HealthCare Technologies Inc.?
GE HealthCare Technologies Inc. has demonstrated a positive profitability trend, with a net profit margin of 10.13% for 2024. The company appears to be creating value, as its return on invested capital (ROIC) of 8.29% exceeds the weighted average cost of capital (WACC) of 8.57%. However, it carries a considerable debt load, with total debt amounting to 9.38B. The company’s rating stands at A-, indicating a solid performance relative to its peers. Nonetheless, it might be prudent to monitor the company’s financial health before making any investment decisions.
Favorable signals
The data presents several favorable elements for GE HealthCare Technologies Inc. The company has a positive gross margin of 41.71%, an EBIT margin of 15.69%, and a net margin of 10.13%. Additionally, the net margin growth stands at an impressive 26.33%. The EPS growth is also favorable at 43.71%. Furthermore, the return on equity (ROE) is strong at 23.59%, and the debt to assets ratio is favorable at 28.34%.
Unfavorable signals
Conversely, there are some unfavorable elements in the data. The revenue growth is at 0.61%, which is considered unfavorable. The price-to-book ratio of 4.22 and the current ratio of 1.0 are also unfavorable. Furthermore, the quick ratio is at 0.79, indicating potential liquidity concerns, and the debt-to-equity ratio is unfavorable at 1.11. Lastly, the dividend yield is low at 0.15%.
Conclusion
Given that the global income statement opinion is favorable while the global ratios opinion is unfavorable, it might be prudent to wait for a more favorable overall assessment before making investment decisions. Additionally, with a recent seller volume higher than buyer volume, it may indicate a need for buyers to return before considering any investment in GE HealthCare Technologies Inc.
Disclaimer: This article is not financial advice. Each investor is responsible for their own investment decisions.
Additional Resources
- GE HealthCare Technologies Inc. $GEHC Stock Position Lifted by Dodge & Cox – MarketBeat (Dec 05, 2025)
- GE HealthCare Technologies Stock: Is GEHC Underperforming the Health Care Sector? – Barchart.com (Dec 05, 2025)
- GE HealthCare Technologies stock: Is GEHC underperforming the health care sector? – MSN (Dec 05, 2025)
- A Fresh Look at GE HealthCare (GEHC) Valuation as Investor Optimism Grows – Yahoo Finance (Dec 01, 2025)
- GEHC Forms 7-Year Care Alliance to Advance URMC Imaging & Monitoring – The Globe and Mail (Dec 05, 2025)
For more information about GE HealthCare Technologies Inc., please visit the official website: gehealthcare.com
